Clinical trial
A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults
NCT02700919 is registered in ClinicalTrials.gov with Mereo BioPharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults
- Lead sponsor
- Mereo BioPharma
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 1, 2016
- Completion date
- November 28, 2017
- Enrollment
- 282 (actual)
- Sites
- 46
Conditions
As the registry lists them; a condition with its own page is linked.